E E Halapy1, A M Chiarelli, N Klar, J Knight. 1. Division of Preventive Oncology, Cancer Care Ontario, 620 University Avenue, Toronto, ON M5G 2L7, Canada. erika.hapaly@cancercare.on.ca
Abstract
OBJECTIVES: To compare breast screening outcomes between women with a moderate or strong family history of breast and/or ovarian cancer with those without such a history. SETTING: The Ontario Breast Screening Programme (OBSP) is a population-based programme offering mammography and clinical breast examination to Ontario women of 50 and older. METHODS: Data from a cohort of 143,574 women screened by the OBSP from 1996 to 1997 were included. Referral rates, cancer detection rates, positive predictive values and the histological features of screen-detected cancers were examined within family history groups, age groups and screening modalities. Logistic regression analysis of cancer detection was conducted to adjust for potential confounding variables; subgroup analysis by hormone replacement therapy (HRT) use was also undertaken. RESULTS: Compared with women with no family history, women with a moderate or strong family history of breast and/or ovarian cancer were more likely to have their cancer detected (odds ratio [OR]=1.44, 95% confidence interval [CI] 1.20-1.74 and OR=1.42, 95% CI 1.10-1.83, respectively). Among women using HRT, however, there was no association observed between family history and cancer detection (moderate: OR=0.98, 95% CI 0.65-1.48; strong: OR=1.17, 95% CI 0.68-2.02) with history. The histological features of invasive tumours were similar among family history groups. CONCLUSIONS: Greater cancer detection rates and high proportions of invasive tumours with good prognosis indicate that women aged 50 and over with a family history may have the potential to benefit from regular breast cancer screening. Further studies are required to identify optimal screening guidelines and to examine whether HRT reduces the ability to detect cancer in these women.
OBJECTIVES: To compare breast screening outcomes between women with a moderate or strong family history of breast and/or ovarian cancer with those without such a history. SETTING: The Ontario Breast Screening Programme (OBSP) is a population-based programme offering mammography and clinical breast examination to Ontario women of 50 and older. METHODS: Data from a cohort of 143,574 women screened by the OBSP from 1996 to 1997 were included. Referral rates, cancer detection rates, positive predictive values and the histological features of screen-detected cancers were examined within family history groups, age groups and screening modalities. Logistic regression analysis of cancer detection was conducted to adjust for potential confounding variables; subgroup analysis by hormone replacement therapy (HRT) use was also undertaken. RESULTS: Compared with women with no family history, women with a moderate or strong family history of breast and/or ovarian cancer were more likely to have their cancer detected (odds ratio [OR]=1.44, 95% confidence interval [CI] 1.20-1.74 and OR=1.42, 95% CI 1.10-1.83, respectively). Among women using HRT, however, there was no association observed between family history and cancer detection (moderate: OR=0.98, 95% CI 0.65-1.48; strong: OR=1.17, 95% CI 0.68-2.02) with history. The histological features of invasive tumours were similar among family history groups. CONCLUSIONS: Greater cancer detection rates and high proportions of invasive tumours with good prognosis indicate that women aged 50 and over with a family history may have the potential to benefit from regular breast cancer screening. Further studies are required to identify optimal screening guidelines and to examine whether HRT reduces the ability to detect cancer in these women.
Authors: Michael A Campitelli; Anna M Chiarelli; Lucia Mirea; Lindsay Stewart; Gord Glendon; Paul Ritvo; Irene L Andrulis; Julia A Knight Journal: Eur J Cancer Prev Date: 2011-11 Impact factor: 2.497
Authors: Li Rita Zhang; Anna M Chiarelli; Gord Glendon; Lucia Mirea; Sarah Edwards; Julia A Knight; Irene L Andrulis; Paul Ritvo Journal: Eur J Cancer Prev Date: 2011-07 Impact factor: 2.497
Authors: Meghan J Walker; Lucia Mirea; Kristine Cooper; Mitra Nabavi; Gord Glendon; Irene L Andrulis; Julia A Knight; Frances P O'Malley; Anna M Chiarelli Journal: Fam Cancer Date: 2014-06 Impact factor: 2.375
Authors: Paul Ritvo; Sarah A Edwards; Gord Glendon; Lucia Mirea; Julia A Knight; Irene L Andrulis; Anna M Chiarelli Journal: BMC Public Health Date: 2012-07-12 Impact factor: 3.295
Authors: Li Rita Zhang; Anna M Chiarelli; Gord Glendon; Lucia Mirea; Julia A Knight; Irene L Andrulis; Paul Ritvo Journal: J Cancer Epidemiol Date: 2012-06-28